Tesamorelin (Metabolic & Body Composition Peptide)

A growth hormone–releasing hormone (GHRH) analogue studied for its effects on growth-hormone signaling, visceral fat, and body composition.

Tesamorelin works upstream by stimulating the pituitary gland to release growth hormone (GH), which subsequently influences IGF-1 and several metabolic processes.

Why Tesamorelin?

🔥 Visceral Fat
Tesamorelin has clinical evidence for reducing visceral adipose tissue (VAT)—the deeper abdominal fat surrounding internal organs—in its approved indication.

⚡ Metabolic Research
Its effects on the GH/IGF-1 axis make tesamorelin relevant to research involving lipid metabolism and body composition.

🧬 Growth Hormone Signaling
Rather than supplying growth hormone directly, tesamorelin mimics GHRH and stimulates the body's own pulsatile GH secretion.

💪 Body Composition
Tesamorelin has been clinically investigated for changes in abdominal fat and other body-composition parameters.

What Makes Tesamorelin Different?

Tesamorelin isn't a GLP-1 medication and doesn't primarily work by suppressing appetite.

Instead, it targets the GHRH → GH → IGF-1 pathway, giving it a fundamentally different mechanism from appetite-focused compounds such as semaglutide, tirzepatide, or cagrilintide.

Product Details

Product: Tesamorelin
Category: Metabolic & Body Composition Peptide
Form: Lyophilized powder
Storage: Keep refrigerated at 2–8°C
Packaging: Individually sealed vial

Tesamorelin is an active pharmaceutical ingredient with an FDA-approved prescription product for reduction of excess abdominal fat in adults with HIV and lipodystrophy. That approval does not establish this particular product as FDA-approved or support general weight-loss use.